NDA 022129 · Shionogi
Ulesfia
Benzyl Alcohol · Topical
NovelDiscontinuedLast checked: Nov 19, 2026Latest source record: Apr 26, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2009
Apr 9, 2009
Approved uses
1
Original approval plus efficacy supplements
Registered trials
44
9 Phase 3, 3 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 9, 2009 Original approval · Type 1 - New Molecular Entity NovelLabelPediatric Medical ReviewPediatric Clinical Pharmacology Review
1 products under this application
- ULESFIA · BENZYL ALCOHOL 5% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · LOTION, TOPICAL · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Benzyl Alcohol" as an intervention, any sponsor and status, largest first.
- Adaptive COVID-19 Treatment Trial 4 (ACTT-4)Pivotal-lookingCompleted
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT04640168 · 1,010 participants · Start Dec 2, 2020 · Primary completion May 18, 2021
Drug: Baricitinib; Dexamethasone and 1 more · For: COVID-19
Sites: Birmingham, Alabama; Fresno, California; La Jolla, California · 72 sites in all
- Hydrocortisone for BPDPivotal-lookingCompleted
NICHD Neonatal Research NetworkResearch network
NCT01353313 · 800 participants · Start Aug 11, 2011 · Primary completion Sep 21, 2020
Drug: Hydrocortisone; Placebo · For: Infant, Newborn; Infant, Small for Gestational Age; Infant, Very Low Birth Weight and 2 more
Sites: Birmingham, Alabama; Los Angeles, California; Palo Alto, California · 20 sites in all
- RCT of Progesterone to Prevent Preterm Birth in Nulliparous Women With a Short CervixPivotal-lookingTerminated
The George Washington University Biostatistics CenterAcademic, hospital or other
NCT00439374 · 657 participants · Start Apr 2007 · Primary completion May 2011
Drug: 17 alpha-hydroxyprogesterone caproate · For: Preterm Delivery; Cervical Length
Sites: Birmingham, Alabama; Chicago, Illinois; Detroit, Michigan · 14 sites in all
- Chlorhexidine vs Povidone Iodine in Alcoholic Solutions for Prevention of Central Venous Catheter InfectionPivotal-lookingCompleted
Poitiers University HospitalAcademic, hospital or other
NCT00259350 · 520 participants · Start May 2004
Drug: Skin disinfection · For: ICU Patients Requiring a Central Venous Access
Sites: Poitiers, France
- A Bioequivalence Study of Pegylated Interferon Alfa-2a (PEG-IFN Alfa-2a) Benzyl Alcohol (BA)-Free Formulation Versus PEG-IFN Alfa-2a (Pegasys) Following Subcutaneous AdministrationPivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT02573025 · 277 participants · Start Sep 17, 2015 · Primary completion Apr 11, 2016
Drug: PEG-IFN alfa-2a BA-free formulation (Test); PEG-IFN alfa-2a market formulation (Reference) · For: Healthy Volunteers
Sites: Adelaide, Australia; Hong Kong, Hong Kong; Shatin, Hong Kong · 9 sites in all
- A Study of the Efficacy, Safety and Pharmacokinetics of RPH-051 and Perjeta® in Combination With Trastuzumab and Docetaxel as the 1st Line Therapy in Patients With HER2-positive Breast CancerPivotal-lookingActive, not recruiting
R-PharmIndustry
NCT07386938 · 246 participants (planned) · Start Aug 9, 2024 · Primary completion Oct 15, 2025
Drug: RPH-051; Docetaxel and 2 more · For: Locally Advanced Breast Cancer; Metastatic Breast Cancer
Sites: Kursk, Russia; Kuz'molovskiy, Russia; Arkhangelsk, Russia · 45 sites in all
- Bioequivalence Study for Benzyl Alcohol Lotion 5%.Pivotal-lookingCompleted
Akorn, Inc.Industry
NCT02624843 · 239 participants · Start Aug 2015 · Primary completion Nov 2015
Drug: Benzyl Alcohol Lotion 5%; Ulesfia (benzyl alcohol lotion) 5% and 1 more · For: Head Lice
Sites: Los Angeles, California; Miami, Florida; Plantation, Florida · 4 sites in all
- A Repeat Insult Patch Test (RIPT) Study Evaluating the Sensitization Potential of Topical SM04755 Solution in Healthy VolunteersPivotal-lookingCompleted
Biosplice Therapeutics, Inc.Industry
NCT03502434 · 223 participants · Start Sep 11, 2017 · Primary completion Nov 17, 2017
Drug: SM04755 · For: Tendinopathy
Sites: Lynchburg, Virginia
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Head lice.
Burgess IF · BMJ Clin Evid 2011 · Systematic Review
- Insect bite reactions.
Singh S, Mann BK · Indian J Dermatol Venereol Leprol 2013 · Systematic Review
- Establishing intravenous access: a study of local anesthetic efficacy.
Nuttall GA, Barnett MR, Smith RL, et al. · Anesth Analg 1993 · Clinical Trial, Randomized Controlled Trial
- Local anesthesia for vein cannulation: a comparison of two solutions.
Brown D · J Infus Nurs 2004 · Clinical Trial, Comparative Study
- A new standardized method of evaluating cutaneous irritation from topical medications.
Uliasz A, Lebwohl M · Cutis 2008 · Controlled Clinical Trial, Research Support, Non-U.S. Gov't
- A phase I safety and pharmacokinetic study of ATX-101: injectable, synthetic deoxycholic acid for submental contouring.
Walker P, Fellmann J, Lizzul PF · J Drugs Dermatol 2015 · Clinical Trial, Phase I, Randomized Controlled Trial
Sponsor: Shionogi
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.